Articles

Ibrutinib Alone or in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Data from the SPARK Study: Mutational Analysis of Patients with Primary Resistance to Ibrutinib in Relapsed/Refractory Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

International Research Agenda for Multicentric Castleman’s Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Updates on Treatments for Castleman’s Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Pathology and Diagnosis of Multicentric Castleman’s Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

The Clinical Features of Multicentric Castleman's Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Multicentric Castleman’s Disease Overview and Update on Its Pathogenesis

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Foundation Medicine on a Molecular Level

Foundation Medicine on a Molecular Level

By Gary Palmer, MD

Personalized Medicine

Dr. Gary Palmer explains how Foundation Medicine is working to improve cancer therapies and personalized medicine on a molecular level.

Personalizing Cancer Treatment Based on a Unique Genetic Profile

By Gary Palmer, MD

Personalized Medicine

Gary Palmer, MD, explains how research is ahead of the physician and patient and the need to educate the physician and patient on all the information about DNA and what drives the cancer.

Is Research Translating to Meaningful Treatment to Patients?

Is Research Translating to Meaningful Treatment to Patients?

By Gary Palmer, MD

Personalized Medicine

Dr. Palmer describes how the direct relationship between treatment directed to change in the DNA actually affects the outcome of patients.

Page 209 of 329